FDA Considering Pricey Implant As Treatment For Opioid Addiction
Amid a raging opioid epidemic, many doctors and families in the U.S. have been pleading for better treatment alternatives.
Amid a raging opioid epidemic, many doctors and families in the U.S. have been pleading for better treatment alternatives.
Starting June 9, terminally ill Californians with six months or less to live can request a doctor’s prescription for medications intended to end their lives peacefully.
If that sounds simple, it won’t be.
Talking about money is never easy.
When California’s aid-in-dying law takes effect this June, terminally ill patients who decide to end their lives could be faced with a hefty bill for the lethal medication. It retails for more than $3,000.
Valeant Pharmaceuticals, the company that makes the drug most commonly prescribed by physicians to aid patients who want to end their lives, doubled the drug’s price last year, one month after California lawmakers proposed legalizing the practice.
Medicare beneficiaries may get dinged with higher prescription drug bills this year because more than half of covered drugs in standalone plans require them to pay a percentage of the cost rather than a flat fee, a new analysis found.
Aetna and Cigna inked deals in early February with drugmaker Novartis that offer the insurers rebates tied to how well a pricey new heart failure drug works to cut hospitalizations and deaths. If the $4,500-a-year drug meets targets, the rebate goes down. Doesn’t work so well?
Medicare plans to test new ways to pay for prescription medications given in doctors’ offices and hospital outpatient centers — moves likely to win praise from some policy experts, b
“My goal is to get everyone eligible on Medicaid and help those moving off Medicaid to insurance,” Lynne Saxton told health policy leaders gathered at the State of Reform on Tuesday.
Most Americans value the prescription products the drug industry produces, but they sure don’t like the prices and want the federal government to take action, according to a new survey.
When it comes to treating chronic conditions, diabetes drugs aren’t nearly as sexy as say, Sovaldi, last year’s breakthrough hepatitis C drug that offers a cure for the chronic liver infection at a price approaching six figures.